Ritholtz Wealth Management boosted its position in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 91.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 15,148 shares of the medical research company’s stock after purchasing an additional 7,241 shares during the quarter. Ritholtz Wealth Management’s holdings in Edwards Lifesciences were worth $1,308,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of EW. Pin Oak Investment Advisors Inc. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $26,000. TrinityBridge Ltd bought a new position in Edwards Lifesciences in the 2nd quarter worth $27,000. GK Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $26,000. Finally, Compass Financial Management LLC bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $32,000. 79.46% of the stock is owned by institutional investors.
Edwards Lifesciences Trading Down 0.2%
Shares of EW opened at $106.95 on Tuesday. The firm has a market capitalization of $61.50 billion, a P/E ratio of 60.42, a P/E/G ratio of 2.82 and a beta of 0.85. The company has a current ratio of 4.60, a quick ratio of 3.86 and a debt-to-equity ratio of 0.05. Edwards Lifesciences Corporation has a 12-month low of $74.66 and a 12-month high of $108.00. The firm has a 50-day moving average price of $90.76 and a 200 day moving average price of $86.44.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. The firm had revenue of $1.72 billion during the quarter, compared to analysts’ expectations of $1.68 billion. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.67 earnings per share. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 3.01 EPS for the current year.
Analysts Set New Price Targets
EW has been the topic of a number of analyst reports. Weiss Ratings upgraded Edwards Lifesciences from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Royal Bank Of Canada lifted their price target on Edwards Lifesciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Rothschild & Co Redburn increased their price target on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Barclays raised their price target on shares of Edwards Lifesciences from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, November 5th. Finally, Argus lifted their price objective on shares of Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Twenty-three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.88.
View Our Latest Stock Analysis on EW
Insider Buying and Selling at Edwards Lifesciences
In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This represents a 12.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 53,945 shares of company stock valued at $5,498,306 over the last ninety days. 0.31% of the stock is currently owned by corporate insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
See Also
- Five stocks we like better than Edwards Lifesciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
